Palonosetron Kalceks

Palonosetron, the active ingredient in Palonosetron Kalceks, is a 5‑HT3 receptor antagonist presented as a 0.075 mg/2 ml solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative settings in adult patients. GNH USA supplies Palonosetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonosetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron Kalceks is a 5‑HT3 receptor antagonist indicated for several clinical situations involving nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting (CINV): Provides prophylaxis against acute and delayed CINV in adult patients receiving moderately to high‑emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgical procedures requiring general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps prevent the onset of nausea and vomiting during radiation treatment. - Antiemetic prophylaxis for patients receiving highly high dose stem cell transplant conditioning regimens.

Palonosetron is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache  - Constipation  - Fatigue  - Diarrhoea  - Dizziness

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis)  - QT‑interval prolongation  - Serotonin syndrome  - Cardiac arrhythmias  - Persistent severe constipation (obstruction).

When using Palitoset ...

- Assess  g  t  ewline -   ewline -  \n ewline   ewline  ewline  ewline ",